BioSpace News Archive

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI) today announced that its SpeedPlate™ Rapid Compression Implant System (“SpeedPlate™”) has received 510(k) clearance from the FDA to be used for fracture fixation, osteotomy fixation, and joint arthrodesis of the foot and ankle.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal clinical trial the Company is executing for the Neovasc Reducer™ (“Reducer”) towards an approval decision for the device in the United States.

Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, today announced that corporate leadership will participate in a fireside chat and one-on-one investor meetings at the 5th Annual Evercore ISI HealthCONx Conference.

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on proprietary peptide engineering technology.

Cambridge Cognition and Luca Healthcare announces a strategic partnership and a 10-year exclusive licensing agreement to commercialize Cambridge Cognition’s suite of cognitive assessment tools in the China market.

VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has announced the availability of VIDA Intelligence Portal 2.0, a major upgrade of its cloud native, AI-enabled Intelligence platform.

On November 26, 2022 , Shanghai Fosun Pharma (Group) Co., Ltd. (“Fosun Pharma”, Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose Dispersion for Injection COVID-19 mRNA Vaccine.

VESTECK, Inc. is pleased to announce that, Dr. Sean Lyden has agreed to assume the role of Chief Medical Consultant and also join the VESTECK Scientific Advisory Board.

On November 21, 2022, Agilex Biolabs was named this year’s winner for the Editor’s Choice Award for “Top company in clinical research-based development”